Last Price$64.9(1.2%)
Market Cap$82.3B
LTM Research & Development Expenses (R&D)
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
5/10
220.8% undervalued
CVS Health Corporation Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for CVS
and see if it's the right time to invest.
CVS Health Corporation (CVS) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
CVS Health CorporationCVS
$0.0
N/A
N/A
N/A
Median Peer Set
$0.0
0.0%
0.0%
0.0%
Bright Health Group, Inc.BHG
$0.0
N/A
N/A
N/A
Cigna CorporationCI
$0.0
N/A
N/A
N/A
Clover Health Investments, Corp.CLOV
$0.0
N/A
N/A
N/A
Centene CorporationCNC
$0.0
N/A
N/A
N/A
Elevance Health Inc.ELV
$0.0
N/A
N/A
N/A
Humana Inc.HUM
$0.0
N/A
N/A
N/A
Alignment Healthcare, Inc.ALHC
$0.0
N/A
N/A
N/A
UnitedHealth Group IncorporatedUNH
$0.0
N/A
N/A
N/A
Oscar Health, Inc.OSCR
$0.0
N/A
N/A
N/A
Molina Healthcare, Inc.MOH
$0.0
N/A
N/A
N/A
CVS key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 37,006.7 21.0% | 43,821.4 18.4% | 76,329.5 74.2% | 87,472.0 14.6% | 98,215.0 12.3% | 95,778.0 (2.5%) | 107,080.0 11.8% | 123,120.0 15.0% | 126,761.0 3.0% | 139,367.0 9.9% | 153,290.0 10.0% | 177,546.0 15.8% | 184,786.0 4.1% | 194,579.0 5.3% | 256,776.0 32.0% | 268,706.0 4.6% | 292,111.0 8.7% | 322,467.0 10.4% | 357,776.0 10.9% | 372,809.0 4.2% |
| Cost of Goods Sold (COGS) | 27,312.1 | 32,079.2 | 60,221.8 | 69,182.0 | 77,857.0 | 75,559.0 | 86,518.0 | 100,632.0 | 102,978.0 | 114,000.0 | 126,762.0 | 148,712.0 | 156,258.0 | 163,041.0 | 211,248.0 | 219,660.0 | 239,991.0 | 267,965.0 | 303,345.0 | 321,408.0 |
% margin | 9,694.6 26.2% | 11,742.2 26.8% | 16,107.7 21.1% | 18,290.0 20.9% | 20,358.0 20.7% | 20,219.0 21.1% | 20,562.0 19.2% | 22,488.0 18.3% | 23,783.0 18.8% | 25,367.0 18.2% | 26,528.0 17.3% | 28,834.0 16.2% | 28,528.0 15.4% | 31,538.0 16.2% | 45,528.0 17.7% | 49,046.0 18.3% | 52,120.0 17.8% | 54,502.0 16.9% | 54,431.0 15.2% | 51,401.0 13.8% |
| Operating Expenses | 7,675.1 | 9,300.6 | 11,314.4 | 12,244.0 | 13,933.0 | 14,082.0 | 14,231.0 | 15,278.0 | 15,746.0 | 16,568.0 | 17,053.0 | 18,448.0 | 18,990.0 | 27,517.0 | 33,541.0 | 35,135.0 | 38,810.0 | 46,548.0 | 40,688.0 | 41,606.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 7,675.1 | 9,300.6 | 11,314.4 | 12,244.2 | 13,933.0 | 14,092.0 | 14,231.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (1,279.0) |
% margin | 2,019.5 5.5% | 2,441.6 5.6% | 4,793.3 6.3% | 6,046.0 6.9% | 6,425.0 6.5% | 6,137.0 6.4% | 6,331.0 5.9% | 7,210.0 5.9% | 8,037.0 6.3% | 8,799.0 6.3% | 9,475.0 6.2% | 10,386.0 5.8% | 9,538.0 5.2% | 4,021.0 2.1% | 11,987.0 4.7% | 13,911.0 5.2% | 13,310.0 4.6% | 7,954.0 2.5% | 13,743.0 3.8% | 8,516.0 2.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 21.0 | 5.0 | 3.0 | 4.0 | 4.0 | 8.0 | 15.0 | 21.0 | 20.0 | 21.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 530.0 | 530.0 | 539.0 | 588.0 | 561.0 | 517.0 | 615.0 | 859.0 | 1,078.0 | 1,062.0 | 2,619.0 | 3,035.0 | 2,907.0 | 2,503.0 | 2,287.0 | 2,658.0 | 2,958.0 |
| Pre-tax Income | 1,909.0 | 2,225.8 | 4,358.7 | 5,537.0 | 5,900.0 | 5,601.0 | 5,747.0 | 6,305.0 | 7,528.0 | 7,678.0 | 8,616.0 | 8,637.0 | 8,268.0 | 1,406.0 | 8,997.0 | 9,770.0 | 10,537.0 | 5,836.0 | 11,173.0 | 6,148.0 |
% effective tax rate | 684.3 35.8% | 856.9 38.5% | 1,721.7 39.5% | 2,193.0 39.6% | 2,200.0 37.3% | 2,179.0 38.9% | 2,258.0 39.3% | 2,436.0 38.6% | 2,928.0 38.9% | 3,033.0 39.5% | 3,386.0 39.3% | 3,317.0 38.4% | 1,637.0 19.8% | 2,002.0 142.4% | 2,366.0 26.3% | 2,569.0 26.3% | 2,548.0 24.2% | 1,509.0 25.9% | 2,805.0 25.1% | 1,562.0 25.4% |
% margin | 1,224.7 3.3% | 1,368.9 3.1% | 2,637.0 3.5% | 3,212.0 3.7% | 3,696.0 3.8% | 3,427.0 3.6% | 3,462.0 3.2% | 3,864.0 3.1% | 4,592.0 3.6% | 4,644.0 3.3% | 5,237.0 3.4% | 5,317.0 3.0% | 6,622.0 3.6% | (594.0) (0.3%) | 6,634.0 2.6% | 7,179.0 2.7% | 8,001.0 2.7% | 4,311.0 1.3% | 8,344.0 2.3% | 4,614.0 1.2% |
| EPS | 1.49 | 1.65 | 1.97 | 2.23 | 2.58 | 2.51 | 2.59 | 3.05 | 3.77 | 3.98 | 4.66 | 4.93 | 6.47 | (0.57) | 5.10 | 5.48 | 6.00 | 3.29 | 6.49 | 3.66 |
| Diluted EPS | 1.45 | 1.60 | 1.92 | 2.18 | 2.55 | 2.49 | 2.57 | 3.03 | 3.74 | 3.96 | 4.63 | 4.90 | 6.44 | (0.57) | 5.08 | 5.46 | 5.95 | 3.26 | 6.47 | 3.66 |
% margin | 2,608.6 7.0% | 3,174.9 7.2% | 5,887.9 7.7% | 7,341.0 8.4% | 7,819.0 8.0% | 7,609.0 7.9% | 7,903.0 7.4% | 8,619.0 7.0% | 9,915.0 7.8% | 10,224.0 7.3% | 11,567.0 7.5% | 12,190.0 6.9% | 11,809.0 6.4% | 6,743.0 3.5% | 16,403.0 6.4% | 17,118.0 6.4% | 17,526.0 6.0% | 12,347.0 3.8% | 18,197.0 5.1% | 13,703.0 3.7% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is CVS Health Corporation's Research & Development Expenses (R&D)?
As of today, CVS Health Corporation's last 12-month Research & Development Expenses (R&D) is $0.0, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is CVS Health Corporation's Research & Development Expenses (R&D) growth rate?
Over the last year, CVS Health Corporation's Research & Development Expenses (R&D) growth was N/A. The average annual Research & Development Expenses (R&D) growth rates for CVS Health Corporation have been N/A over the past three years, N/A over the past five years.